TiGenix
<b>Head Office</b>
Technologielaan 3
Leuven
B - 3001
Tel: 32-16-39-60-60
Fax: 32-16-39-60-70
Website: http://www.tigenix.com/
Email: bd@tigenix.com
183 articles about TiGenix
-
Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period
7/31/2018
TiGenix becomes a wholly owned subsidiary of Takeda
-
Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix
7/6/2018
The number of Securities tendered into the Bid, together with all Securities owned by Takeda and its affiliates, represents or gives access to 96.03% of the voting rights represented or given access to by all of the outstanding Securities on a fully diluted basis.
-
Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period
6/6/2018
Takeda Pharmaceutical Company Limited and TiGenix NV today announced the results of the first acceptance period of Takeda’s previously announced tender offer in cash for all outstanding ordinary shares, warrants and American Depositary Shares of TiGenix that are not yet owned by Takeda and its affiliates.
-
Takeda Announces Information Related to its Pending Voluntary and Conditional Public Takeover Bid for Outstanding Shares and American Depositary Shares of TiGenix
5/23/2018
Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced information related to its previously announced and ongoing tender offer (the “Bid”) in cash for all outstanding ordinary shares (“Ordinary Shares”), warrants (“Warrants”) and American Depositary Shares (“ADSs”) of TiGenix.
-
UPDATED: Takeda Pharma and Shire Come Back to the Negotiating Table and Offer is Set at $64 Billion
4/24/2018
Takeda Pharmaceutical has come back with an improved bid for Shire, making it the fifth round of talks. -
Takeda Pharmaceutical has come back to the bargaining table with a juicier bid for Shire. Yesterday, Takeda’s $60 billion-plus bid for Shire took an odd turn late yesterday when Dublin, Ireland-based Allergan was reported to be in talks with Shire as well. However, by the end of the day, Allergan...
-
TiGenix: Transparency Information - Feb. 7, 2018
2/7/2018
Following the issuance of 413,283 new shares on February 6, 2018 resulting from the exercise of 413,283 warrants of TiGenix NV, the transparency data have changed as follows (status on February 6, 2018):
-
Cryoport to Provide TiGenix With Cutting Edge Cold Chain Logistics for Clinical Trial of SEPCELL for the Treatment of Sepsis
2/5/2018
TiGenix aims to recruit 180 patients in at least 50 centers for the randomized double-blind placebo controlled SEPCELL study.
-
Tigenix: Transparency Notifications Pursuant to Article 14 of the Law Of May 2, 2007 - Feb. 1, 2018
2/1/2018
The notice concerns the following two transparency notifications:
-
Tigenix: Transparency Notifications Pursuant to Article 14 of the Law of May 2, 2007 – Jan. 29, 2018
1/29/2018
It concerns the following four transparency notifications received from Bank of America Corporation.
-
Tigenix: Transparency Notification Pursuant to Article 14 of the Law of May 2, 2007 – Jan. 19, 2018
1/19/2018
On January 16, 2018, TiGenix received a transparency notification from JPMorgan Chase & Co., following the disposal of voting securities or voting rights on January 9, 2018.
-
Tigenix: Transparency Notifications Pursuant to Article 14 of the Law of May 2, 2007 - Jan. 17, 2018
1/17/2018
It concerns the following two notifications:
-
Tigenix: Transparency Notifications Pursuant to Article 14 of the Law of May 2, 2007
1/15/2018
It concerns the following four notifications:
-
Tigenix Announces Publication in Gastroenterology of 52-Week Results of the Phase III ADMIRE-CD Trial of Cx601
1/15/2018
The one-year data also confirmed the favorable safety and tolerability profile of Cx601 reported at week 24.
-
Will this new buy be enough for Celgene investors?
-
Shares of TiGenix shot up more than 72 percent in pre-market trading after the deal was announced.
-
TiGenix Confirms Strategic Focus on Cx601 and its Adipose Derived Stem Cell (eASC) Platform
12/20/2017
This decision follows the recent positive CHMP opinion for Cx601 to treat complex perianal fistulas in Crohn's disease.
-
Takeda And Tigenix Announce That Cx601 (Darvadstrocel) Has Received a Positive CHMP Opinion to Treat Complex Perianal Fistulas in Crohn's Disease
12/15/2017
This recommendation marks the first allogeneic stem cell therapy to receive a positive CHMP opinion in Europe.
-
Mesoblast Grants Tigenix an Exclusive Global Patent License to Use Adipose-Derived Mesenchymal Stem Cells in the Local Treatment of Fistulae
12/15/2017
The agreement includes the right for TiGenix to grant sub-licenses to affiliates and third parties, including TiGenix’s current development and commercialization partner ex-United States.
-
JPMorgan Chase & Co Notifies 3.12% Shareholding in TiGenix
11/27/2017
TiGenix publishes today a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.